<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Psychiatry</journal-id><journal-id journal-id-type="pmc">IJPsy</journal-id><journal-title-group><journal-title>Indian Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0019-5545</issn><issn pub-type="epub">1998-3794</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21206792</article-id><article-id pub-id-type="pmc">2950952</article-id><article-id pub-id-type="publisher-id">IJPsy-46-333</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lalit</surname><given-names>Vaya</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Appaya</surname><given-names>Prakash M.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hegde</surname><given-names>Rajendra P.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mital</surname><given-names>Anukant K.</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mittal</surname><given-names>Sunil</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Nagpal</surname><given-names>Rajesh</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Palaniappun</surname><given-names>Vaiapuri</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ramsubramaniam</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Rao</surname><given-names>Gundugurti P.</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Roy</surname><given-names>Krishna</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Trivedi</surname><given-names>Jitendra K.</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Vankar</surname><given-names>Ganpat K.</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Karan</surname><given-names>Rajesh S.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Sweety</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Ronak B.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Clinical Research, Torrent Research Centre, Village Bhat, Dist. Gandhinagar-382 428. <email xlink:href="lalitvaya@torrentpharma.com.">lalitvaya@torrentpharma.com.</email></aff><aff id="aff2"><label>2</label>Department of Psychiatry, St. John's Medical college &#x00026; Hospital, Bangalore.</aff><aff id="aff3"><label>3</label>Consultant Psychiatrist, Goa.</aff><aff id="aff4"><label>4</label>Department of Psychiatry, Rajiv Gandhi Medical college &#x00026; Chattrapati shivaji Hospital, Thane.</aff><aff id="aff5"><label>5</label>Consultant Psychiatrist &#x00026; Psychotherapist, Delhi Psychiatry center, Delhi.</aff><aff id="aff6"><label>6</label>Consultant Psychiatrist, Manobal Klinik, Delhi.</aff><aff id="aff7"><label>7</label>Department of Psychiatry, Madras medical college &#x00026; research institute, Chennai.</aff><aff id="aff8"><label>8</label>Consultant Psychiatrist, M.S. Chellamuthu Trust &#x00026; Research foundation, Madurai.</aff><aff id="aff9"><label>9</label>Consultant psychiatrist, Woodland Asha Neuro Psychiatric center, Hyderabad.</aff><aff id="aff10"><label>10</label>Department of Psychiatry, N.R.S. Medical College, Kolkatta.</aff><aff id="aff11"><label>11</label>Department of Psychiatry, K. G. Medical College Lucknow.</aff><aff id="aff12"><label>12</label>Department of Psychiatry, B.J. medical College and Civil hospital, Ahmedabad.</aff><author-notes><corresp id="cor1"><label>*</label>Correspondence</corresp></author-notes><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2004</year></pub-date><volume>46</volume><issue>4</issue><fpage>333</fpage><lpage>341</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Psychiatry</copyright-statement><copyright-year>2004</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The present randomized, double blind, parallel group, controlled, multi-centric trial was designed to evaluate the efficacy and tolerability of escitalopram in comparison with citalopram and sertraline in the treatment of major depressive disorder. Outpatients (N=214) with an ongoing/newly diagnosed ICD-10 major depressive episode and a Hamilton Rating Scale for Depression (HAM-D) score of &#x0003e; 18 were randomly assigned to citalopram, 20&#x02013;40 mg/day (74 patients), escitalopram, 10&#x02013;20 mg/day (69 patients) and sertraline, 50-150 mg/day (71 patients), for a 4-week double-blind treatment period, with dosage adjustment (after 2 weeks of treatment) according to the response to treatment. Clinical response was evaluated by the 17 items HAM-D and the Clinical Global Impression (CGI) scales, which were recorded at baseline and at weekly intervals. Tolerability was evaluated by observed/spontaneously reported adverse changes in laboratory parameters (baseline and after 4 weeks). Response rate was defined as a decrease in HAM-D score by 50% from baseline and remission rate was defined as a HAM-D score of &#x0003c; 8. Response rate at the end of two week were 58% for escitalopram (10mg/day), 49% for citalopram (20mg/day) and 52% for sertraline (50-100mg/day). Response rate at the end of four week were 90% for escitalopram (10-20mg/day), 86% for citalopram (20-40mg/day) and 97% for sertraline (100-150mg/day). The Remission rates at the end of four weeks were 74% for escitalopram, 65% for citalopram and 77% for sertraline. Adverse experiences were reported by 45% of patients in escitalopram group, 58% patients in citalopram and 56% patients in the sertraline group. Additionally, there were lesser dropouts and  lesser requirement for dose escalation in escitalopram than in citalopram and sertraline group. In conclusion Escitalopram, the Senantiomer of the citalopram is a safe and effective antidepressant in the Indian population. It has potentially superior efficacy than citalopram and a comparable efficacy to sertraline with fewer side effects than both citalopram and sertraline.</p></abstract><kwd-group><kwd>Escitalopram</kwd><kwd>Sertraline</kwd><kwd>Citalopram</kwd><kwd>SSRI&#x02032;s</kwd></kwd-group></article-meta></front></article>